Skip to main content

Market Overview

GW Pharma's Epidiloex Data Is Good News For Zynerba

Share:
GW Pharma's Epidiloex Data Is Good News For Zynerba

GW Pharmaceuticals PLC (NASDAQ: GWPH)'s stock gained more than 17 percent Monday following the company's announcement of a second successful pivotal trial in an ongoing Phase 3 trial exploring its lead cannabinoid product, Epidiolex.

GW Pharma's strong gains helped boost shares of other pharmaceutical companies that develop and commercialize cannabinoid therapeutics. Specifically, Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) saw its stock gain more than 10 percent following the announcement.

According to analysts at Jefferies, Zynerba is similarly investing synthetic cannabinoids in epilepsy delivered trandermally. Specifically, ZYN002 (CBD gel) is being explored by the company and it has initiated a Phase 2 STAR-2 trial.

Related Link: Cantor Raises GW Pharma's Target To $182 Following Second Successful Phase 3 Trial

Zynerba's primary endpoint for its study is the median percentage change in seizure frequencies over a 12-week treatment period and data is expected to be released in the first half of 2017.

"One key trial design difference is the baseline period in the ZYNE trials will have a duration of 8-weeks to evaluate seizure frequency and type of seizure whereas in the GWPH PIII trials the baseline period was a duration of 4-weeks," the analysts noted. "Furthermore, ZYNE does not require a 2-week dose titration in its dosing regimen."

Bottom line, the analysts suggested investors have "not appreciated" Zynerba's CBD program and GW Pharma's data is a "positive read through" for ZYN002.

Shares of Zynerba are Buy rated with a $32 price target.

Latest Ratings for ZYNE

DateFirmActionFromTo
Jul 2020NeedhamDowngradesBuyHold
May 2020Cantor FitzgeraldMaintainsOverweight
Oct 2019NeedhamInitiates Coverage OnBuy

View More Analyst Ratings for ZYNE
View the Latest Analyst Ratings

 

Related Articles (ZYNE)

View Comments and Join the Discussion!

Posted-In: Cannabinoid Drugs CBD GelAnalyst Color Long Ideas Health Care Analyst Ratings Trading Ideas General Best of Benzinga

Latest Ratings

StockFirmActionPT
LBCredit SuisseMaintains36.0
TRGPCredit SuisseMaintains40.0
SNOWCredit SuisseMaintains275.0
DARCredit SuisseMaintains95.0
CLRMKM PartnersDowngrades26.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com